Brief: Petros Pharma Engages Massachusetts General Hospital In Sponsored Research Agreement For Tissue-Specific Oxygenation Sensor Technology
26/04/2022 14:27
April 26 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS, INC. ENGAGES MASSACHUSETTS GENERAL
HOSPITAL IN A SPONSORED RESEARCH AGREEMENT FOR TISSUE-SPECIFIC
OXYGENATION SENSOR TECHNOLOGY
* PETROS - WILL ENTER AGREEMENT FOR OPTION TO NEGOTIATE
EXCLUSIVE
LICENSE OF TISSUE-SPECIFIC OXYGENATION SENSOR WITHIN SPECIFIC
HUMAN TISSUES
* PETROS PHARMACEUTICALS INC - PLANS TO APPLY
TISSUE-SPECIFIC
OXYGENATION SENSOR TECHNOLOGY TO POTENTIALLY ENHANCE EXISTING
ERECTILE DEVICE THERAPY
Source text for Eikon: ID:nGNX2SJCkc
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions